Paracrine Therapeutics

What Paracrine Therapeutics does

Paracrine Therapeutics Pte. Ltd. is a Singapore-based, privately held clinical-stage biotechnology company founded in 2015. The company develops mesenchymal stromal cell (MSC)-derived exosome therapeutics, positioning cell-free extracellular vesicles as a delivery mechanism for regenerative and anti-inflammatory biologic activity across multiple disease areas. Its lead clinical programme is a topical MSC exosome ointment for psoriasis, which has completed a Phase 1 safety and tolerability trial in Singapore; the broader pipeline spans osteochondral repair, corneal scarring and ocular surface diseases, cardiovascular repair, neurodegenerative disorders, and radiation injury.

The core platform combines proprietary cell engineering, exosome manufacturing, and lyophilisation technologies. An immortalised MSC line provides a stable and renewable source for exosome production, and the company's lyophilisation process converts exosomes into a dry formulation to preserve biological activity and enable long-term storage and distribution. The technology is supported by a substantial intellectual property estate: Research Director Dr. Lim Sai Kiang, a Clarivate Highly Cited Researcher (2021–2024), holds over 100 granted patents covering MSC-derived extracellular vesicles as cell-free therapeutics.

The company's business model is preclinical and clinical development rather than commercial revenue generation. No products have reached approval, no revenue has been disclosed, and pricing has not been set. Go-to-market activity is presently limited to clinical trial operations in Singapore, scientific publications, and stated strategic collaborations with academic institutions, clinicians, and global pharmaceutical partners. Distribution will ultimately flow through pharmaceutical channels upon regulatory approval. Leadership includes CEO Stephen Lim (30+ years across healthcare, biotech, and SGX-listed companies) and Executive Director Ms Liu Ye (former Monetary Authority of Singapore and Singapore banking), with a Scientific Advisory Board drawn from A*STAR's Bioprocessing Technology Institute and a manufacturing consultant with biopharmaceutical industry experience.

Name

Paracrine Therapeutics

Legal name

Paracrine Therapeutics Pte. Ltd.

Website

https://paracrinetherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Paracrine Therapeutics is a Singapore-based, clinical-stage biotechnology company founded in 2015 developing MSC-derived exosome therapeutics for psoriasis, ophthalmology, orthopedics, cardiovascular, and neurodegenerative indications. Its lead programme has completed Phase 1.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Exosome therapeutics
• Regenerative medicine
• Cell-free therapy
• MSC biotechnology
• Lyophilised biologics

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels5 records

Core offering

Paracrine Therapeutics develops MSC-derived exosome therapeutics as cell-free regenerative biologics, combining proprietary cell engineering, exosome manufacturing, and lyophilisation technologies into a unified platform. Its lead clinical asset is a topical MSC exosome ointment for psoriasis (Phase 1 completed in Singapore), with a broader pipeline targeting osteochondral repair, corneal scarring and ocular surface diseases, cardiovascular repair, neurodegenerative diseases, and radiation injury. The lyophilisation process converts exosomes into a stable dry formulation for improved storage, transportation, and clinical translation.

Product overview

Paracrine Therapeutics is a clinical-stage biotechnology company offering a unified platform of MSC-derived exosome therapeutics. The core product is the PT Exosome Platform, which combines proprietary exosome technology with lyophilisation technology for stable formulations. The lead clinical programme is MSC Exosome Ointment for psoriasis (Phase 1 completed). The therapeutic pipeline spans multiple disease areas including osteochondral repair, corneal scarring and ocular surface diseases, cardiovascular repair, neurodegenerative disorders, and radiation injury. The lyophilisation module enables enhanced stability and extended shelf life for the exosome therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

• MSC Exosome Ointment (Topical Exosome Therapy) Lead clinical-stage topical exosome ointment candidate for the treatment of psoriasis; Phase 1 safety and tolerability trial completed in Singapore. Intended as a cell-free regenerative therapeutic for inflammatory skin disease.
• PT Exosome Platform MSC-derived exosome therapeutics platform delivering cell-free regenerative biologics for inflammatory diseases, ophthalmology, orthopedics, and neurodegenerative disorders. Designed for consistent, scalable, and clinically translatable exosome production.
• Lyophilisation Technology Proprietary freeze-drying process that stabilises MSC-derived exosomes while preserving their biological activity. Converts exosomes into a dry formulation to improve product stability, long-term storage, and distribution logistics for therapeutic use.
• Osteochondral Repair Programme Pipeline therapeutic programme applying MSC-derived exosome therapeutics to support osteochondral (cartilage and bone) tissue repair in orthopaedic indications.
• Corneal Scarring and Ocular Surface Disease Programme Pipeline therapeutic programme applying MSC-derived exosome therapeutics to treat corneal scarring and other ocular surface diseases in ophthalmology.
• Cardiovascular Repair Programme Pipeline therapeutic programme applying MSC-derived exosome therapeutics to support cardiovascular repair and regenerative treatment of heart disease.
• Neurodegenerative Disease Programme Pipeline therapeutic programme applying MSC-derived exosome therapeutics to neurodegenerative disorders where tissue repair and modulation of inflammatory pathways are clinically relevant.
• Radiation Injury Research Programme Research programme investigating the use of MSC extracellular vesicles (exosomes) to mitigate the effects of radiation injury on tissues.

Quantifiable outcome

• Phase 1 clinical trial completed demonstrating safety and tolerability of MSC exosome ointment for psoriasis treatment
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Academic InstitutionscoreStrategic or Co-development PartnerStrategic collaborations with leading academic institutions for research and development of exosome therapeutics, translating scientific discoveries into clinical applications
• ClinicianscoreStrategic or Co-development PartnerCollaborations with clinicians to advance clinical programmes and support therapeutic development through clinical expertise and patient access
• Global Pharmaceutical PartnerscoreStrategic or Co-development PartnerStrategic collaborations with global pharmaceutical companies for development and potential commercialisation of exosome therapeutics worldwide

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Others

• Stemcell Technologies: Provider of MSC and stem cell research tools, reagents, and culture systems. Included as an adjacent/ecosystem participant because it supplies enabling technologies used across the MSC and exosome therapeutic field, including by Paracrine's pipeline customers and academic collaborators.

Broad incumbents

• Pluristem Therapeutics: Clinical-stage cell therapy company using placenta-derived mesenchymal-like cells for inflammatory, muscle, and haematological indications. Broad incumbent because both companies operate in regenerative/cell-based therapeutics for chronic inflammatory and degenerative conditions.
• Mesoblast: Commercial-stage allogeneic MSC-based cell therapy company with approved product Ryoncil and late-stage programmes in inflammatory and cardiovascular indications. Broad incumbent because Mesoblast uses the same MSC biological source as Paracrine, but delivers living cells rather than exosomes.
• Healios K.K. (formerly Athersys): Japanese cell therapy company developing MultiStem (multipotent adult progenitor cell) therapies for stroke, ARDS, and inflammatory indications. Broad incumbent due to overlap in regenerative medicine target indications and biological approach using stem-cell derived therapeutics.

Emerging players

• Codiak BioSciences: Pioneering engineered exosome therapeutics company (engEx platform) that advanced multiple programmes into the clinic before restructuring. Emerging player due to high technology overlap in MSC-derived/exposome therapeutics despite its reduced operational footprint.
• ExoCoBio: South Korea-based clinical-stage company developing MSC-derived exosome therapeutics for atopic dermatitis, alopecia, and regenerative applications. Emerging player because it competes in overlapping dermatology and regenerative indications with a similar MSC-exosome modality.
• Rion LLC: Mayo Clinic spin-out developing platelet-derived and MSC-derived extracellular vesicle therapeutics for wound healing, orthopedics, and inflammatory conditions. Emerging player because it competes in overlapping indication areas (e.g., orthopedics) using a closely related extracellular vesicle modality.

Direct peers

• Evox Therapeutics: UK-based clinical-stage biotech engineering exosome-based therapeutics for rare diseases. Direct peer because both companies develop engineered/cell-derived extracellular vesicle therapeutics using similar biological chassis and face the same regulatory, manufacturing, and clinical translation challenges.
• Direct Biologics: Clinical-stage US biotech developing bone marrow-derived MSC extracellular vesicle (ExoFlo) therapeutics for inflammatory conditions, wound healing, and orthopedics. Direct peer due to near-identical MSC-derived exosome modality and overlapping indication focus.
• Capricor Therapeutics: Clinical-stage biotech developing cell-derived and exosome-based therapeutics, notably CAP-1002 (cardiac cell therapy) and exosome programmes for inflammatory and rare indications. Direct peer due to overlapping cell-derived therapeutic modality and pipeline overlap in regenerative applications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/codevz2
• Facebookfacebook.com/Codevz
• Instagraminstagram.com/codevz

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paracrine Therapeutics